Aptose Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aptose Biosciences generated cash of -$44,590,000, which is less than the previous year. Cash used in financing activities reached the amount of $6,910,000 last year. Net change in cash is therefore -$27,718,000.
Cash Flow
| 2014 | -9.94K | -7.52K | 10.06K |
|---|---|---|---|
| 2015 | -9.12M | 5.68M | 707.65K |
| 2016 | -12.22M | 6.20M | 5.61M |
| 2017 | -10.29M | -743K | 13.71M |
| 2018 | -23.20M | 12K | 27.87M |
| 2019 | -21.55M | -17.37M | 103.44M |
| 2020 | -33.89M | 12.62M | 58.80M |
| 2021 | -43.30M | -35.20M | 226K |
| 2022 | -32.32M | 30.06M | 116K |
| 2023 | -44.59M | 9.96M | 6.91M |
APS.TO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.97M | 39.11M | 117.39M | 79.84M | 15.29M | 10.63M | 7.94M | 8.55M | 10.35M | 631 |
Operating activities | ||||||||||
Net income | -51.20M | -41.82M | -65.35M | -55.23M | -26.27M | -28.86M | -11.66M | -13.85M | -10.53M | -11.50K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 466K | 528K | 622K | 614K | 613K | 87K | 84K | 114.57K | 69.17K | 32 |
Stock-based compensation expense | 3.65M | 5.20M | 12.94M | 21.43M | 2.29M | 0 | 817K | 1.50M | 2.02M | 2.40K |
| Deferred income tax benefit | 3.65M | 5.20M | 12.94M | 21.43M | 2.29M | 0 | 817K | 1.50M | 2.02M | 2.40K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -280K | 4.62M | -472K | 211K | 645K | 726K | 0 | 0 | 191.68K | 0 |
Cash generated by operating activities | -44.59M | -32.32M | -43.30M | -33.89M | -21.55M | -23.20M | -10.29M | -12.22M | -9.12M | -9.94K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -34.99M | 0 | -17.26M | 0 | -798K | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -29K | -24K | -212K | -79K | -102K | -329K | -13K | -3.71K | -237.80K | -301 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 9.96M | 30.06M | -35.20M | 12.62M | -17.37M | 12K | -743K | 6.20M | 5.68M | -7.52K |
Financing activities | ||||||||||
Common Stock Issued | 6.88M | 101K | 36K | 58.40M | 93.16M | 25.72M | 500K | 5.61M | 8K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -552 |
Cash used in financing activities | 6.91M | 116K | 226K | 58.80M | 103.44M | 27.87M | 13.71M | 5.61M | 707.65K | 10.06K |
Net Change In Cash | -27.71M | -2.14M | -78.27M | 37.55M | 64.54M | 4.66M | 2.69M | -625.69K | -2.06M | 17.20K |
Cash at end of period | 9.25M | 36.97M | 39.11M | 117.39M | 79.84M | 15.29M | 10.63M | 7.93M | 8.28M | 17.83K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |